The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee, MD, MS, Miami Cancer Institute, Miami, FL, comments on results from a Phase I study (NCT01545141) of a neoadjuvant chemokine-modulating regimen of interferon alpha, rintatolimod, and celecoxib in resectable metastatic colorectal cancer. The regimen was safe and feasible, with no dose-limiting toxicities. All patients underwent complete resection. Tissue analysis demonstrated favorable immune modulation within the tumor microenvironment, including increased effector T-cell ratios. These findings support further investigation of this approach combined with immunotherapy or chemotherapy to improve oncologic outcomes. This interview took place during the 2026 ASCO Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We’ve presented the results from a Phase I study where we used systemic chemokine modulation to alter the tumor microenvironment in colorectal cancer patients with liver metastasis. This represents an extension of our work from our prior Phase II clinical trial, where we showed that a systemic chemokine modulation can change the tumor microenvironment and can potentially make immune-resistant tumors more immune-sensitive...
We’ve presented the results from a Phase I study where we used systemic chemokine modulation to alter the tumor microenvironment in colorectal cancer patients with liver metastasis. This represents an extension of our work from our prior Phase II clinical trial, where we showed that a systemic chemokine modulation can change the tumor microenvironment and can potentially make immune-resistant tumors more immune-sensitive. So the Phase I study basically looked at the resectable population where patients had resectable liver metastases from colorectal cancer. And what we showed was that such a combination was safe, but also we saw preliminary activity that this combination was able to change the tumor microenvironment. So the next steps should be really looking at combining immune checkpoint inhibitors or other forms of immunotherapy with systemic chemokine modulation.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
